Contact
- address:
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Dr Galsky is a medical oncologist focused on the care of patients with bladder cancer. He received his medical degree from Tufts University School of Medicine and subsequently completed training in Internal Medicine at Beth Israel-Deaconess Medical Center/Harvard Medical School. He completed a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center where he served as Chief Fellow. During his fellowship, Dr Galsky was fortunate to be mentored by leaders in the field on bladder cancer research and treatment and after completing training, he joined the faculty at Sloan-Kettering to pursue work in this area. In 2010, he was recruited to the Tisch Cancer Institute/Mount Sinai School of Medicine as Director of Genitourinary Medical Oncology where he is currently a Professor of Medicine. Dr Galsky’s research has focused on the clinical development of novel therapies for bladder cancer, dissecting the clinical basis for heterogeneity in patient outcomes, and understanding the disconnect between the efficacy and effectiveness of available treatments. His current research extends these efforts to team science-based approaches focused on dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Disclosures
- Grant/research support, honoraria or consultation fees: Merck, Pfizer, Astrazeneca, BMS, Astellas, Jannsen, Seattle Canada, Genentech
- Stocks, shares or equity/ contract of employment or named position on a company board: Rappta Rherapeutics